Communicating scientific evidence: drugs for Alzheimer's disease as a case study
| dc.rights.license | open | en_US |
| dc.contributor.author | KEPP, Kasper P | |
| dc.contributor.author | HOILUND-CARLSEN, Poul F | |
| dc.contributor.author | CRISTEA, Ioana A | |
| dc.contributor.author | CUMMING, Robert G | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | DALY, Timothy | |
| dc.contributor.author | EMILSSON, Louise | |
| dc.contributor.author | FLACCO, Maria E | |
| dc.contributor.author | HEMKENS, Lars G | |
| dc.contributor.author | JANIAUD, Perrine | |
| dc.contributor.author | JOHNSEN, Kasper B | |
| dc.contributor.author | LALLUKKA, Tea | |
| dc.contributor.author | MUKA, Taulant | |
| dc.contributor.author | NAUDET, Florian | |
| dc.contributor.author | REVHEIM, Mona-Elisabeth R | |
| dc.contributor.author | SQUITTI, Rosanna | |
| dc.contributor.author | THAMBISETTY, Madhav | |
| dc.date.accessioned | 2025-04-15T13:43:41Z | |
| dc.date.available | 2025-04-15T13:43:41Z | |
| dc.date.issued | 2025-02-05 | |
| dc.identifier.issn | 1473-4877 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/206211 | |
| dc.description.abstractEn | This paper reviews the scientific evidence on new anti-amyloid monoclonal antibodies for treating Alzheimer's disease as a case study for improving scientific evidence communication. We introduce five guidelines condensed from the biomedical evidence literature but adapted to the short format of science communication in e.g., journal opinion pieces and newspaper articles. Given the major importance and recent confusion regarding the discussed drugs, with certain disagreements seen e.g., between FDA and EMA, the suggested guidelines may be useful to clinicians discussing with their patients and to scientists communicating the evidence in balance. More generally, we hope that the guidelines may help us to improve communication of scientific evidence on complex topics in opinion pieces in the scientific literature, in advocacy, and in media appearances. | |
| dc.language.iso | EN | en_US |
| dc.subject.en | Alzheimer’s Disease | |
| dc.subject.en | Evidence | |
| dc.subject.en | Donanemab | |
| dc.subject.en | Health Policy | |
| dc.subject.en | Lecanemab | |
| dc.subject.en | Science Communication | |
| dc.title.en | Communicating scientific evidence: drugs for Alzheimer's disease as a case study | |
| dc.title.alternative | Curr Med Res Opin | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1080/03007995.2025.2458530 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 39853750 | en_US |
| bordeaux.journal | Current Medical Research and Opinion | en_US |
| bordeaux.page | 347-354 | en_US |
| bordeaux.volume | 41 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.issue | 2 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | PHARES_BPH | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.popular | non | en_US |
| hal.audience | Internationale | en_US |
| hal.export | false | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Current%20Medical%20Research%20and%20Opinion&rft.date=2025-02-05&rft.volume=41&rft.issue=2&rft.spage=347-354&rft.epage=347-354&rft.eissn=1473-4877&rft.issn=1473-4877&rft.au=KEPP,%20Kasper%20P&HOILUND-CARLSEN,%20Poul%20F&CRISTEA,%20Ioana%20A&CUMMING,%20Robert%20G&DALY,%20Timothy&rft.genre=article |
Fichier(s) constituant ce document
| Fichiers | Taille | Format | Vue |
|---|---|---|---|
|
Il n'y a pas de fichiers associés à ce document. |
|||